Seminars in Cancer Biology

Article	Citations
Editorial Board	624
Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation	444
Emerging applications of bacteria as antitumor agents	403
Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications	362
Expression of concern “Decoding T cell senescence in cancer: Is revisiting required?” [Semin. Cancer Biol. 108 (2025) 33–47]	358
Microbiome-modulated immunotherapy in oncology: Current applications and future prospects	304
Small secretory proteins of immune cells can modulate gynecological cancers	280
Advances in biology and novel treatments of SCLC	248
Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator	245
Deregulated transcription factors in the emerging cancer hallmarks	234
Critical DNA damaging pathways in tumorigenesis	231
Multifaceted role of chemokines in solid tumors: From biology to therapy	224
Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation	222
The impact of obesity and lipids on cancer: Insights into mechanisms and potential interventions	220
The emerging role of metabolic interventions in uveal melanoma	213
Enhancing head and neck tumor management with artificial intelligence: Integration and perspectives	206
The IL-1 family in tumorigenesis and antitumor immunity	200
Anticancer properties of chimeric HDAC and kinase inhibitors	182
Editorial Board	181
Special issue: Deregulated transcription factors in the cancer therapeutic challenges: An update on cancer stemness features	180
Origins and molecular effects of hypoxia in cancer	179
Association of Chlamydia and Mycoplasma infections with susceptibility to ovarian cancer: A systematic review and meta-analysis	177
Immune cellular components and signaling pathways in the tumor microenvironment	164
Extracellular vesicles associated microRNAs: Their biology and clinical significance as biomarkers in gastrointestinal cancers	160
Cracking the resistance code: The molecular reclassification of cancer and precision therapy strategies	156

Innovative trial design in precision oncology	154
Erratum to “RNA regulatory mechanisms controlling TGF-β signaling and EMT in cancer” [Semin. Cancer Biol. 102–103 (2024) 4–16]	152
Gut microbes in gastrointestinal cancers	152
Expression of concern: “Combined targeting of senescent cells and senescent macrophages: A new idea for integrated treatment of lung cancer” [Semin. Cancer Biol. 106–107 (2024) 43–57]	151
Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy	148
Excess body weight and postmenopausal breast cancer: Emerging molecular mechanisms and perspectives	147
Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics?	145
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy	143
Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer	142
Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics	139
Genome chaos: Creating new genomic information essential for cancer macroevolution	139
Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools	133
Editorial Board	125
Therapy-induced modulation of extracellular vesicles in hepatocellular carcinoma	124
Integrating biomarkers, experimental models, genomics, and novel therapeutics for pancreatic cancer precision medicine	123
Lipid metabolism in cancer is regulated by the integrated natural product–miRNA–target axis	123
Metabolic landscape and rewiring in normal hematopoiesis, leukemia and aging	122
How far have we explored fungi to fight cancer?	122
Expression of concern “Immunosenescence in digestive system cancers: Mechanisms, research advances, and therapeutic strategies” [Semin. Cancer Biol. 106–107 (2024) 234–250]	121
Editorial Board	120
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine	119
Reprogramming of glycolysis by chemical carcinogens during tumor development	117
The role of deiodinases on metabolic alteration in cancer	114
Regulation of the aryl hydrocarbon receptor in cancer and cancer stem cells of gynecological malignancies: An update on signaling pathways	114
Targeting the “undruggable”: RNA-binding proteins in the spotlight in cancer therapy	113
Vibrational spectroscopy for decoding cancer microbiota interactions: Current evidence and future perspective	111
Atrial fibrillation in cancer patients: Epidemiology, identification and management	107
Anticancer natural products targeting immune checkpoint protein network	105
Systemic lipid metabolic alterations and the tumor microenvironment: A hidden driver of immune dysfunction	104
Insight into the role of multiple signaling pathways in regulating cancer stem cells of gynecologic cancers	101
Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics	100
Multi-omic markers of intraductal papillary mucinous neoplasms progression into pancreatic cancer	100
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors	97
Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems	95
Editorial Board	94
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer	94
Editorial Board	94
Cytotoxic activity of l-lysine alpha-oxidase against leukemia cells	90
Clinical utility of whole-genome sequencing in precision oncology	89
Editorial Board	89
BubR1 and SIRT2: Insights into aneuploidy, aging, and cancer	88
Role of ubiquitination-driven metabolisms in oncogenesis and cancer therapy	87
Chaperonins in cancer: Expression, function, and migration in extracellular vesicles	87
Mechanisms and applications of apolipoproteins and apolipoprotein mimetic peptides: Common pathways in cardiovascular disease and cancer	87
Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer	87
Mitochondria in sarcoma and carcinoma: Achilles’ heel or Hercules’ strength?	87
Transcription networks rewire gene repertoire to coordinate cellular reprograming in prostate cancer	86
Functionalized-DNA nanostructures as potential targeted drug delivery systems for cancer therapy	85
Drivers of centrosome abnormalities: Senescence progression and tumor immune escape	85
Microorganisms in cancer tertiary lymphoid structure formation	84

The foundational framework of tumors: Gametogenesis, p53, and cancer	84
The microbiome-immune cell interaction network: Advancing tumor immunotherapy	83
Analytical demands to use whole-genome sequencing in precision oncology	83
Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling	83
Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications	80
Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders	80
Microbiota and lung cancer	80
Metabolic reprogramming of tumor microenviroment by engineered bacteria	80
Advancements in small cell lung cancer	79
Cancer therapy-related cardiovascular toxicity: Current progress and future perspectives	78
Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment	77
Microbes in gynecologic cancers: Causes or consequences and therapeutic potential	76
Urinary microbiota and bladder cancer: A systematic review and a focus on uropathogens	76
Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme	75
Paradoxes of cancer: Survival at the brink	75
Beyond cardiovascular health: The pharmacotherapeutic potential of statins in oncology	75
Editorial Board	75
Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer	74
Chemopreventive effects of anthocyanins on colorectal and breast cancer: A review	74
Sanitation enzymes: Exquisite surveillance of the noncanonical nucleotide pool to safeguard the genetic blueprint	73
Holistic immunomodulation for small cell lung cancer	73
Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications	72
Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment	71
Novel molecular regulators of breast cancer stem cell plasticity and heterogeneity	71
CRISPR/Cas mediated epigenome editing for cancer therapy	71
Excess body weight: Novel insights into its roles in obesity comorbidities	70
Anticancer activity of lactic acid bacteria	70
Targeting tumor cell senescence and polyploidy as potential therapeutic strategies	69
Special Issue: Epigenetic regulation of cancer progression: Promises and progress	69
Editorial Board	69
Thematic issue ‘tumor glycolysis’	68
Non-coding genome in small cell lung cancer between theoretical view and clinical applications	68
Editorial Board	68
Editorial Board	68
Microbial metabolites for cancer immunotherapy: Current evidence and future directions	67
Exosome-based nanomedicine for cancer treatment by targeting inflammatory pathways: Current status and future perspectives	67
Accelerating antibody discovery and design with artificial intelligence: Recent advances and prospects	67
Human cell polyploidization: The good and the evil	66
Deregulated transcription factors and poor clinical outcomes in cancer patients	66
Beyond cell cycle regulation: The pleiotropic function of CDK4 in cancer	66
Characterizing and exploiting the many roles of aberrant H2B monoubiquitination in cancer pathogenesis	66
The intricate role of adipokines in cancer-related signaling and the tumor microenvironment: Insights for future research	65
TGF-β, EMT, and resistance to anti-cancer treatment	65
The impact of VEGF on cancer metastasis and systemic disease	65
The crucial role of epigenetic regulation in breast cancer anti-estrogen resistance: Current findings and future perspectives	65
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges	65
Obesity, type 2 diabetes and cancers of the digestive system	65
The role of RNA-binding proteins in the processing of mRNAs produced by carcinogenic papillomaviruses	63
Editorial Board	62
Microbiome unlocks cancer immunotherapeutic potential: State of the art and future	62
Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?	62
Precision diagnostics in lymphomas – Recent developments and future directions	61
Transcriptional factors targeting in cancer stem cells for tumor modulation	61
Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspective	61
Inflammation-targeted nanomedicine against brain cancer: From design strategies to future developments	60
The intricate nature of senescence in development and cell plasticity	60
Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance	59
Extracellular vesicles as source for the identification of minimally invasive molecular signatures in glioblastoma	59
Mechanisms and strategies of immunosenescence effects on non-small cell lung cancer (NSCLC) treatment: A comprehensive analysis and future directions	59
cGAS/STING signalling pathway in senescence and oncogenesis	59
Emerging role of pancreatic stellate cell-derived extracellular vesicles in pancreatic cancer	59
The Warburg effect: The hacked mitochondrial-nuclear communication in cancer	59
Contributions of the distinct biophysical phenotype of polyploidal giant cancer cells to cancer progression	58
Obesity and main urologic cancers: Current systematic evidence, novel biological mechanisms, perspectives and challenges	58
Alternative splicing in EMT and TGF-β signaling during cancer progression	57
Artificial intelligence aids in development of nanomedicines for cancer management	57
Cathepsins: Emerging targets in the tumor ecosystem to overcome cancers	56
Editorial Board	56
Gut microbiota and immunosenescence in cancer	56
Editorial Board	56
Remodeling of tumor microenvironment by cellular senescence and immunosenescence in cervical cancer	56
Editorial Board	55
Corrigendum to “How far have we explored fungi to fight cancer?” [86/Part 2 (2022) 976–989]	55
Precision medicine in pediatric solid cancers	54
Pro-tumoral functions of tumor-associated macrophage EV-miRNA	54
Pancreatic neuroendocrine neoplasms (pNENs): Genetic and environmental biomarkers for risk of occurrence and prognosis	54
Inflammation targeted nanomedicines: Patents and applications in cancer therapy	53
A role for partial epithelial-to-mesenchymal transition in enabling stemness in homeostasis and cancer	53
The role of exercise in obesity-related cancers: Current evidence and biological mechanisms	53
Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways	52

Targeting oncogenic transcription factors in skin malignancies: An update on cancer stemness and therapeutic outcomes	52
Small cell lung cancer: Novel treatments beyond immunotherapy	52
New insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy	52
Impaired cholesterol and LDL uptake pathways in the development of oncological and cardiovascular diseases	51
Interplay of ferroptosis, cuproptosis, and PANoptosis in cancer treatment-induced cardiotoxicity: Mechanisms and therapeutic implications	51
Nanoparticles: Attractive tools to treat colorectal cancer	51
The altered lipidome of hepatocellular carcinoma	51
Epigenetic deregulation in cancer: Enzyme players and non-coding RNAs	50
Vitamin D: What role in obesity-related cancer?	50
Exploiting transcription factors to target EMT and cancer stem cells for tumor modulation and therapy	50
Hedgehog signaling mechanism and role in cancer	50